{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:54Z","timestamp":1792512174565,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11030-024-10886-w","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:44:12Z","timestamp":1717494252000},"page":"991-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Designing a novel drug\u2013drug conjugate as a prodrug for breast cancer therapy: in silico insights"],"prefix":"10.1007","volume":"29","author":[{"given":"Sankar","family":"Muthumanickam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balajee","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyaraman","family":"Jeyakanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonamuthu","family":"Jegatheswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boomi","family":"Pandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"10886_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119305","volume":"273","author":"BZ Sibuh","year":"2021","unstructured":"Sibuh BZ, Khanna S, Taneja P, Sarkar P, Tanejam N (2021) Molecular docking, synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7 human breast cancer cell line. Life Sci 273:119305. https:\/\/doi.org\/10.1016\/j.lfs.2021.119305","journal-title":"Life Sci"},{"key":"10886_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1155\/2021\/4759821","volume":"2021","author":"GM Safwat","year":"2021","unstructured":"Safwat GM, Hassanin K, Mohammed ET, Ahmed EK, Abdel Rheim MR, Ameen MA, Abdel-Aziz M, Gouda AM, Peluso I, Almeer R-D (2021) Synthesis, anticancer assessment, and molecular docking of novel chalcone-thienopyrimidine derivatives in HepG2 and MCF-7 cell lines. Oxid Med Cell Longev 2021:7. https:\/\/doi.org\/10.1155\/2021\/4759821","journal-title":"Oxid Med Cell Longev"},{"issue":"10","key":"10886_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/biomedicines9101375","volume":"9","author":"BZ Sibuh","year":"2021","unstructured":"Sibuh BZ, Gupta PK, Taneja P, Khanna S, Sarkar P, Pachisia S, Khan AA, Jha NK, Dua K, Singh SKP (2021) Synthesis, in silico study, and anti-cancer activity of thiosemicarbazone derivatives. Biomedicines 9(10):1375. https:\/\/doi.org\/10.3390\/biomedicines9101375","journal-title":"Biomedicines"},{"issue":"1","key":"10886_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang TY (2021) Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther 6(1):201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w","journal-title":"Signal Transduct Target Ther"},{"key":"10886_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1021\/mp9000662","volume":"6","author":"C Peetla","year":"2009","unstructured":"Peetla C, Stine A, Labhasetwar V (2009) Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm 6:1264\u20131276. https:\/\/doi.org\/10.1021\/mp9000662","journal-title":"Mol Pharm"},{"key":"10886_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M (2017) Breast cancer. Lancet 389:1134\u20131150. https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8","journal-title":"Lancet"},{"key":"10886_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2020.00733","volume":"11","author":"W Cui","year":"2020","unstructured":"Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S (2020) Discovering anti-cancer drugs via computational methods. Front Pharmacol 11:733. https:\/\/doi.org\/10.3389\/fphar.2020.00733","journal-title":"Front Pharmacol"},{"key":"10886_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jconrel.2018.04.019","volume":"279","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang X, Deng F, Zheng N, Liang Y, Zhang H, He B, Dai W, Wang X, Zhang Q (2018) The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles. J Control Release 279:136\u2013146. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.019","journal-title":"J Control Release"},{"key":"10886_CR9","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/bi300620c","volume":"51","author":"D Utepbergenov","year":"2012","unstructured":"Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, Lannigan DA, Stukenberg PT, Derewenda ZS (2012) Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 \u00c5 crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Biochemistry 51:6499\u20136510. https:\/\/doi.org\/10.1021\/bi300620c","journal-title":"Biochemistry"},{"key":"10886_CR10","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1038\/emm.2016.61","volume":"48","author":"YY Park","year":"2016","unstructured":"Park YY, Nam HJ, Do M, Lee JH (2016) The p90 ribosomal S6 kinase 2 specifically affects mitotic progression by regulating the basal level, distribution and stability of mitotic spindles. Exp Mol Med 48:e250\u2013e250. https:\/\/doi.org\/10.1038\/emm.2016.61","journal-title":"Exp Mol Med"},{"key":"10886_CR11","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-16-0106","volume":"15","author":"KA Ludwik","year":"2016","unstructured":"Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O\u2019Doherty GA, Lannigan GA (2016) Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer. Mol Cancer Ther 15:2598\u20132608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0106","journal-title":"Mol Cancer Ther"},{"key":"10886_CR12","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41388-020-01447-0","volume":"39","author":"LY Li","year":"2020","unstructured":"Li LY, Chen XS, Wang KS, Guan YD, Ren XC, Cao DS, Sun XY, Li AX, Tao YG, Zhang Y, Yin MZ (2020) RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPK\u03b12-mediated autophagy. Oncogene 39:6704\u20136718. https:\/\/doi.org\/10.1038\/s41388-020-01447-0","journal-title":"Oncogene"},{"key":"10886_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1021\/ol0500463","volume":"7","author":"DJ Maloney","year":"2005","unstructured":"Maloney DJ, Hecht SM (2005) Synthesis of a potent and selective inhibitor of p90 Rsk. Org Lett 7:1097\u20131099. https:\/\/doi.org\/10.1021\/ol0500463","journal-title":"Org Lett"},{"key":"10886_CR14","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1021\/acs.molpharmaceut.9b00359","volume":"16","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li Y, Tian H, Zhu Q, Wang F, Fan Z, Zhou S, Wang X, Xie L, Hou Z (2019) Redox-responsive and dual-targeting hyaluronic acid\u2013methotrexate prodrug self-assembling nanoparticles for enhancing intracellular drug self-delivery. Mol Pharm 16:3133\u20133144. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00359","journal-title":"Mol Pharm"},{"key":"10886_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejphar.2013.04.049","volume":"713","author":"AA Kabel","year":"2013","unstructured":"Kabel AA, Abdel-Rahman MN, El-Sisi AEDE, Haleem MS, Ezzat NM, El Rashidy MA (2013) Effect of atorvastatin and methotrexate on solid Ehrlich tumor. Eur J Pharmacol 713:47\u201353","journal-title":"Eur J Pharmacol"},{"key":"10886_CR16","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1021\/mp3002232","volume":"9","author":"TP Thomas","year":"2012","unstructured":"Thomas TP, Huang B, Choi SK, Silpe JE, Kotlyar A, Desai AM, Zong H, Gam J, Joice M, Baker JR (2012) Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharm 9:2669\u20132676. https:\/\/doi.org\/10.1021\/mp3002232","journal-title":"Mol Pharm"},{"key":"10886_CR17","doi-asserted-by":"publisher","first-page":"27040","DOI":"10.1021\/acsami.5b09112","volume":"7","author":"H Ma","year":"2015","unstructured":"Ma H, He C, Cheng Y, Yang Z, Zang J, Liu J, Chen X (2015) Localized co-delivery of doxorubicin, cisplatin, and methotrexate by thermosensitive hydrogels for enhanced osteosarcoma treatment. ACS Appl Mater Interfaces 7:27040\u201327048. https:\/\/doi.org\/10.1021\/acsami.5b09112","journal-title":"ACS Appl Mater Interfaces"},{"key":"10886_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.bcp.2010.11.014","volume":"8","author":"WY Huang","year":"2011","unstructured":"Huang WY, Yang PM, Chang YF, Marquez VE, Chen CC (2011) Methotrexate induces apoptosis through p53\/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC\/EZH2. Biochem Pharmacol 8:1510\u20131517. https:\/\/doi.org\/10.1016\/j.bcp.2010.11.014","journal-title":"Biochem Pharmacol"},{"key":"10886_CR19","first-page":"2036","volume":"48","author":"A Lorico","year":"1988","unstructured":"Lorico A, Toffoli G, Boiocchi M, Erba E, Broggini M, Rappa G, D\u2019Incalci M (1988) Accumulation of DNA strand breaks in cells exposed to methotrexate or N 10-propargyl-5, 8-dideazafolic acid. Can Res 48:2036\u20132041","journal-title":"Can Res"},{"key":"10886_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S152312","author":"J Xie","year":"2018","unstructured":"Xie J, Fan Z, Li Y, Zhang Y, Yu F, Su G, Xie L, Hou Z (2018) Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy. Int J Nanomed. https:\/\/doi.org\/10.2147\/IJN.S152312","journal-title":"Int J Nanomed"},{"key":"10886_CR21","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1021\/mp400269z","volume":"11","author":"J Chen","year":"2014","unstructured":"Chen J, Huang L, Lai H, Lu C, Fang M, Zhang Q, Luo X (2014) Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharm 11:2213\u20132223. https:\/\/doi.org\/10.1021\/mp400269z","journal-title":"Mol Pharm"},{"key":"10886_CR22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.22037\/ijpr.2017.2133","volume":"16","author":"M Ghadiri","year":"2017","unstructured":"Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Hosseinkhani H (2017) In-vitro assessment of magnetic dextran-spermine nanoparticles for capecitabine delivery to cancerous cells. Iranian J Pharm Res 16:1320. https:\/\/doi.org\/10.22037\/ijpr.2017.2133","journal-title":"Iranian J Pharm Res"},{"key":"10886_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/21691401.2018.1559179","volume":"47","author":"R Nazari-Vanani","year":"2019","unstructured":"Nazari-Vanani R, Karimian K, Azarpira N, Heli H (2019) Capecitabine-loaded nanoniosomes and evaluation of anticancer efficacy. Artificial Cells Nanomed Biotechnol 47:420\u2013426. https:\/\/doi.org\/10.1080\/21691401.2018.1559179","journal-title":"Artificial Cells Nanomed Biotechnol"},{"key":"10886_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2014.04.002","volume":"349","author":"H Shi","year":"2014","unstructured":"Shi H, Jiang J, Ji J, Shi M, Cai Q, Chen X, Yu Y, Liu B, Zhu Z, Zhang J (2014) Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett 349:128\u2013135. https:\/\/doi.org\/10.1016\/j.canlet.2014.04.002","journal-title":"Cancer Lett"},{"key":"10886_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/pharmaceutics12100978","volume":"12","author":"JH Jang","year":"2020","unstructured":"Jang JH, Jeong SH, Lee YB (2020) Enhanced lymphatic delivery of methotrexate using W\/O\/W nanoemulsion: in vitro characterization and pharmacokinetic study. Pharmaceutics 12:978. https:\/\/doi.org\/10.3390\/pharmaceutics12100978","journal-title":"Pharmaceutics"},{"key":"10886_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10965-022-03422-7","volume":"30","author":"U Rehman","year":"2023","unstructured":"Rehman U, Sarfraz RM, Mahmood A, Mahmood T, Batool N, Haroon B, Benguerba Y (2023) Tamarind\/\u03b2-CD-g-poly (MAA) pH responsive hydrogels for controlled delivery of Capecitabine: fabrication, characterization, toxicological and pharmacokinetic evaluation. J Polym Res 30:41. https:\/\/doi.org\/10.1007\/s10965-022-03422-7","journal-title":"J Polym Res"},{"key":"10886_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.417","volume":"6","author":"M Hasan","year":"2018","unstructured":"Hasan M, Leak RK, Stratford RE, Zlotos DP, Witt-Enderby PA (2018) Drug conjugates\u2014an emerging approach to treat breast cancer. Pharmacol Res Perspect 6:e00417. https:\/\/doi.org\/10.1002\/prp2.417","journal-title":"Pharmacol Res Perspect"},{"key":"10886_CR28","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1021\/acs.molpharmaceut.5b00005","volume":"12","author":"T Zhang","year":"2015","unstructured":"Zhang T, Huang P, Shi L, Su Y, Zhou L, Zhu X, Yan D (2015) Self-assembled nanoparticles of amphiphilic twin drug from floxuridine and bendamustine for cancer therapy. Mol Pharm 12:2328\u20132336. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00005","journal-title":"Mol Pharm"},{"key":"10886_CR29","doi-asserted-by":"publisher","first-page":"21452","DOI":"10.1039\/D2RA03451D","volume":"12","author":"D Halder","year":"2022","unstructured":"Halder D, Das S, Aiswarya R, Jeyaprakash RS (2022) Molecular docking and dynamics based approach for the identification of kinase inhibitors targeting PI3K\u03b1 against non-small cell lung cancer: a computational study. RSC Adv 12:21452\u201321467. https:\/\/doi.org\/10.1039\/D2RA03451D","journal-title":"RSC Adv"},{"key":"10886_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2021.107509","volume":"93","author":"U Panwar","year":"2021","unstructured":"Panwar U, Singh SK (2021) In silico virtual screening of potent inhibitor to hamper the interaction between HIV-1 integrase and LEDGF\/p75 interaction using E-pharmacophore modeling, molecular docking, and dynamics simulations. Comput Biol Chem 93:107509. https:\/\/doi.org\/10.1016\/j.compbiolchem.2021.107509","journal-title":"Comput Biol Chem"},{"key":"10886_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2203259","author":"S Muthumanickam","year":"2023","unstructured":"Muthumanickam S, Ramachandran B, Boomi P, Jeyakanthan J, Prabu HG, Jegatheswaran S, Premkumar K (2023) Combination of bendamustine-azacitidine against Syk target of breast cancer: an in silico study. J Biomol Struct Dynam. https:\/\/doi.org\/10.1080\/07391102.2023.2203259","journal-title":"J Biomol Struct Dynam"},{"key":"10886_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijbiomac.2018.05.023","volume":"116","author":"MF AlAjmi","year":"2018","unstructured":"AlAjmi MF, Rehman MT, Hussain A, Rather GM (2018) Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents. Int J Biol Macromol 116:173\u2013181. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.05.023","journal-title":"Int J Biol Macromol"},{"key":"10886_CR33","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1080\/07391102.2020.1830855","volume":"40","author":"S Muthumanickam","year":"2022","unstructured":"Muthumanickam S, Indhumathi T, Boomi P, Balajee R, Jeyakanthan J, Anand K, Ravikumar S, Kumar P, Sudha A, Jiang Z (2022) In silico approach of naringin as potent phosphatase and tensin homolog (PTEN) protein agonist against prostate cancer. J Biomol Struct Dyn 40:1629\u20131638. https:\/\/doi.org\/10.1080\/07391102.2020.1830855","journal-title":"J Biomol Struct Dyn"},{"issue":"3","key":"10886_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11030-022-10475-9","volume":"27","author":"HO Rasul","year":"2023","unstructured":"Rasul HO, Aziz BK, Ghafour DD, Kivrak A (2023) Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach. Mol Diversity 27(3):1141\u20131162. https:\/\/doi.org\/10.1007\/s11030-022-10475-9","journal-title":"Mol Diversity"},{"issue":"5","key":"10886_CR35","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s11030-022-10556-9","volume":"27","author":"HO Rasul","year":"2023","unstructured":"Rasul HO, Aziz BK, Ghafour DD, Kivrak A (2023) Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: An in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction. Mol Diversity 27(5):2273\u20132296. https:\/\/doi.org\/10.1007\/s11030-022-10556-9","journal-title":"Mol Diversity"},{"issue":"1","key":"10886_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00894-021-05010-w","volume":"28","author":"HO Rasul","year":"2022","unstructured":"Rasul HO, Aziz BK, Ghafour DD, Kivrak A (2022) In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer. J Mol Model 28(1):17. https:\/\/doi.org\/10.1007\/s00894-021-05010-w","journal-title":"J Mol Model"},{"key":"10886_CR37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ijbiomac.2018.08.052","volume":"120","author":"V Suryanarayanan","year":"2018","unstructured":"Suryanarayanan V, Rajavel T, Devi KP, Singh SK (2018) Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain. Int J Biol Macromol 120:823\u2013834. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.052","journal-title":"Int J Biol Macromol"},{"key":"10886_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13205-021-02797-6","volume":"11","author":"MK Thirunavukkarasu","year":"2021","unstructured":"Thirunavukkarasu MK, Shin WH, Karuppasamy R (2021) Exploring safe and potent bioactives for the treatment of non-small cell lung cancer. Biotech 11:241. https:\/\/doi.org\/10.1007\/s13205-021-02797-6","journal-title":"Biotech"},{"key":"10886_CR39","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1080\/07391102.2018.1546618","volume":"37","author":"S-C Eduardo","year":"2019","unstructured":"Eduardo S-C, Betancourt-Conde I, Hern\u00e1ndez-Campos A, T\u00e9llez-Valencia A, Castillo R (2019) In silico hit optimization toward AKT inhibition: fragment-based approach, molecular docking and molecular dynamics study. J Biomol Struct Dyn 37:4301\u20134311. https:\/\/doi.org\/10.1080\/07391102.2018.1546618","journal-title":"J Biomol Struct Dyn"},{"key":"10886_CR40","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1038\/srep06948","volume":"4","author":"HN Banavath","year":"2014","unstructured":"Banavath HN, Sharma OP, Kumar MS, Baskaran R (2014) Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep 4:6948. https:\/\/doi.org\/10.1038\/srep06948","journal-title":"Sci Rep"},{"key":"10886_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2021.100811","volume":"27","author":"P Satapathy","year":"2021","unstructured":"Satapathy P, Prakash JK, More SS, Chandramohan V, Zameer F (2021) Structural modulation of dual oxidase (Duox) in Drosophila melanogaster by phyto-elicitors: A free energy study with molecular dynamics approach. Inform Med Unlocked 27:100811. https:\/\/doi.org\/10.1016\/j.imu.2021.100811","journal-title":"Inform Med Unlocked"},{"key":"10886_CR42","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1080\/07391102.2019.1674695","volume":"38","author":"S Chinnasamy","year":"2020","unstructured":"Chinnasamy S, Selvaraj C, Kaushik AC, Kaliamurthi S, Chandrabose S, Singh S, Thirugnanasambandam S, Gu K, Wei DQ (2020) Molecular docking and molecular dynamics simulation studies to identify potent AURKA inhibitors: assessing the performance of density functional theory, MM-GBSA and mass action kinetics calculations. J Biomol Struct Dynam 38:4325\u20134335. https:\/\/doi.org\/10.1080\/07391102.2019.1674695","journal-title":"J Biomol Struct Dynam"},{"key":"10886_CR43","doi-asserted-by":"publisher","first-page":"32234","DOI":"10.1021\/acsomega.0c03871","volume":"5","author":"AK Maurya","year":"2020","unstructured":"Maurya AK, Mulpuru V, Mishra N (2020) Discovery of novel coumarin analogs against the \u03b1-glucosidase protein target of Diabetes mellitus: Pharmacophore-based QSAR, docking, and molecular dynamics simulation studies. ACS Omega 5:32234\u201332249. https:\/\/doi.org\/10.1021\/acsomega.0c03871","journal-title":"ACS Omega"},{"key":"10886_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130049","volume":"10","author":"H Chen","year":"2015","unstructured":"Chen H, Yao K, Chang X, Shim JH, Kim HG, Malakhova M, Kim DJ, Bode AM, Dong Z (2015) Computational and biochemical discovery of RSK2 as a novel target for epigallocatechin gallate (EGCG). PLoS ONE 10:e0130049. https:\/\/doi.org\/10.1371\/journal.pone.0130049","journal-title":"PLoS ONE"},{"key":"10886_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fonc.2013.00201","volume":"3","author":"A Arul","year":"2013","unstructured":"Arul A, Cho YY (2013) A rising cancer prevention target of RSK2 in human skin cancer. Front Oncol 3:201. https:\/\/doi.org\/10.3389\/fonc.2013.00201","journal-title":"Front Oncol"},{"key":"10886_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.130667","volume":"1241","author":"A Safavi","year":"2021","unstructured":"Safavi A, Ghodousi ES, Ghavamizadeh M, Sabaghan M, Azadbakht O, Babaei H, Nazeri Z, Darabi MK, Zarezade V (2021) Computational investigation of novel farnesyltransferase inhibitors using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking and molecular dynamics simulation studies: A new insight into cancer treatment. J Mol Struct 1241:130667","journal-title":"J Mol Struct"},{"key":"10886_CR47","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari R, Kumar R (2014) Open source drug discovery consortium A. Lynn, g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951\u20131962. https:\/\/doi.org\/10.1021\/ci500020m","journal-title":"J Chem Inf Model"},{"key":"10886_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1039\/C4SC03030C","volume":"6","author":"S Er","year":"2015","unstructured":"Er S, Suh C, Marshak MP, Aspuru-Guzik A (2015) Computational design of molecules for an all-quinone redox flow battery. Chem Sci 6:885\u2013893. https:\/\/doi.org\/10.1039\/C4SC03030C","journal-title":"Chem Sci"},{"key":"10886_CR49","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1021\/acs.bioconjchem.5b00513","volume":"26","author":"M Hu","year":"2015","unstructured":"Hu M, Huang P, Wang Y, Su Y, Zhou L, Zhu X, Yan D (2015) Synergistic combination chemotherapy of camptothecin and floxuridine through self-assembly of amphiphilic drug\u2013drug conjugate. Bioconjug Chem 26:2497\u20132506. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00513","journal-title":"Bioconjug Chem"},{"key":"10886_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.634097","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Zhang F, Xiao X, Guo Y, Wen Z, Li M, Pu X (2021) Prediction of synergistic drug combinations for prostate cancer by transcriptomic and network characteristics. Front Pharmacol 12:634097. https:\/\/doi.org\/10.3389\/fphar.2021.634097","journal-title":"Front Pharmacol"},{"key":"10886_CR51","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8:38022. https:\/\/doi.org\/10.18632\/oncotarget.16723","journal-title":"Oncotarget"},{"key":"10886_CR52","doi-asserted-by":"publisher","DOI":"10.47176\/mjiri.35.158","author":"NT Dastjerd","year":"2021","unstructured":"Dastjerd NT, Gheibi N, Yazdi HA, Shariatifar H, Farasat A (2021) Design and characterization of liposomal methotrexate and its effect on BT-474 breast cancer cell line. Med J Islamic Republic Iran. https:\/\/doi.org\/10.47176\/mjiri.35.158","journal-title":"Med J Islamic Republic Iran"},{"key":"10886_CR53","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4103\/1735-5362.217432","volume":"12","author":"M Mohammadian","year":"2017","unstructured":"Mohammadian M, Zeynali S, Azarbaijani AF, Ansari MHK, Kheradmand F (2017) Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci 12:517. https:\/\/doi.org\/10.4103\/1735-5362.217432","journal-title":"Res Pharm Sci"},{"key":"10886_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.460","volume":"7","author":"S Kern","year":"2017","unstructured":"Kern S, Truebenbach I, H\u00f6hn M, Gorges J, Kazmaier U, Zahler S, Vollmar AM, Wagner E (2017) Combined antitumoral effects of pretubulysin and methotrexate. Pharmacol Res Perspect 7:e00460. https:\/\/doi.org\/10.1002\/prp2.460","journal-title":"Pharmacol Res Perspect"},{"key":"10886_CR55","doi-asserted-by":"publisher","first-page":"001","DOI":"10.4999\/uhod.15634","volume":"32","author":"EM Altundag","year":"2015","unstructured":"Altundag EM, Yilmaz AM, Corek C, Yalcin AS, Yavuz TAGA, Kocturk S (2015) Synergistic effects of methotrexate and suberoylanilide hydroxamic acid in triggering apoptosis of chronic myeloid leukemia cells. Int J Hematol Oncol 32:001\u2013011. https:\/\/doi.org\/10.4999\/uhod.15634","journal-title":"Int J Hematol Oncol"},{"key":"10886_CR56","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1021\/acs.bioconjchem.6b00503","volume":"27","author":"Y Wang","year":"2016","unstructured":"Wang Y, Huang P, Hu M, Huang W, Zhu X, Yan D (2016) Self-delivery nanoparticles of amphiphilic methotrexate-gemcitabine prodrug for synergistic combination chemotherapy via effect of deoxyribonucleotide pools. Bioconjug Chem 27:2722\u20132733. https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00503","journal-title":"Bioconjug Chem"},{"key":"10886_CR57","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/aps.2013.16","volume":"34","author":"XL Cheng","year":"2013","unstructured":"Cheng XL, Zhou TY, Li B, Li MY, Li L, Li ZQ, Lu W (2013) Methotrexate and 5-aminoimidazole-4-carboxamide riboside exert synergistic anticancer action against human breast cancer and hepatocellular carcinoma. Acta Pharmacol Sin 34:951\u2013959","journal-title":"Acta Pharmacol Sin"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10886-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10886-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:38:38Z","timestamp":1741955918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10886-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10886"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10886-w","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"31 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}